(Q53594098)

16 May 2018

title

Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. (English)

1 reference

16 May 2018

0 references

1 reference

Eisenberg JD

1

1 reference

16 May 2018

Aitken ML

2

1 reference

16 May 2018

Dorkin HL

3

1 reference

16 May 2018

Harwood IR

4

1 reference

16 May 2018

Ramsey BW

5

1 reference

16 May 2018

Schidlow DV

6

1 reference

16 May 2018

Wilmott RW

7

1 reference

16 May 2018

Wohl ME

8

1 reference

16 May 2018

Fuchs HJ

9

1 reference

16 May 2018

Christiansen DH

10

1 reference

16 May 2018

Smith AL

11

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 July 1997

1 reference

16 May 2018

The Journal of Pediatrics

published in

1 reference

16 May 2018

volume

131

1 reference

16 May 2018

issue

1 Pt 1

1 reference

16 May 2018

page(s)

118-124

1 reference

16 May 2018

Liquefaction of viscous purulent exudates by deoxyribonuclease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

PURIFICATION AND PROPERTIES OF DESOXYRIBONUCLEASE ISOLATED FROM BEEF PANCREAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

A new prognostic score and clinical evaluation system for cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Single breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique. Statement of the American Thoracic Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Standardization of lung function testing in children. Proceedings and Recommendations of the GAP Conference Committee, Cystic Fibrosis Foundation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Standardization of spirometry--1987 update. Statement of the American Thoracic Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Comparison of scales used to quantitate the sense of effort to breathe in patients with chronic obstructive pulmonary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Immunogenicity of recombinant DNA human insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Deoxyribonuclease in the treatment of purulent bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Aerosolized pancreatic dornase and antibiotics in pulmonary infections: use in patients with postoperative and nonoperative infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Dornase Aerosol Effect on Sputum Viscosity in Cases Of Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Allergic reactions of the lungs to enzymes of Bacillus subtilis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Immediate Hypersensitivity to Hog Trypsin Resulting from Industrial Exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

Respiratory hazards from proteolytic enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970134-3

10.1016/S0022-3476(97)70134-3

7 January 2021

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018